Get the Stockscreener App
23.87
1.36%
-0.33
Pre-market:
23.85
-0.02
-0.08%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $23.87, with a volume of 40.51M.
It is down -1.36% in the last 24 hours and up +3.92% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$24.20
Open:
$24.2
24h Volume:
40.51M
Relative Volume:
0.85
Market Cap:
$130.73B
Revenue:
$62.46B
Net Income/Loss:
$7.88B
P/E Ratio:
17.30
EPS:
1.38
Net Cash Flow:
$9.84B
1W Performance:
+3.56%
1M Performance:
+3.92%
6M Performance:
-14.72%
1Y Performance:
-14.17%
1-Day Range:
$23.85
$24.25
1-Week Range:
$22.46
$24.44
52-Week Range:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.87 | 130.73B | 62.46B | 7.88B | 9.84B | 1.38 |
|
LLY
Lilly Eli Co
|
821.46 | 737.81B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.00 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
196.07 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
69.12 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
113.08 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Recombinant Human Endostatin Market Top PlayersPfizer Inc., - openPR.com
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April - The Motley Fool
Pfizer Stock Up 5% Following Q1 Results: Time To Buy, Sell Or Hold? - Barchart.com
Analyst recommendations: Amazon, PepsiCo, Linde, Pfizer, Crowdstrike Holdings... - marketscreener.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Anti Suicide Drugs Market Detailed In New Research Report 2025 | - openPR.com
Is Pfizer Inc. (PFE) The Most Profitable Cheap Stock to Buy Now? - Insider Monkey
Is Pfizer Inc.'s (NYSE:PFE) Stock Price Struggling As A Result Of Its Mixed Financials? - Yahoo Finance
West Virginia counties, cities to receive Pfizer settlement checks - WBOY.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025) - 24/7 Wall St.
Drug Discovery Market Is Booming So Rapidly 2025-2032Pfizer - openPR.com
Pfizer Inc (PFE-N) Stock Price and News - The Globe and Mail
Do Wall Street Analysts Like Pfizer Stock? - Nasdaq
Zacks.com featured highlights Centene, Pediatrix Medical, Pfizer, StoneCo and Banco Santander - Nasdaq
Pfizer donates $250K to Oklahoma Tribal health clinics - The Journal Record
What's Next For Pfizer Stock After A Mixed Q1? - Nasdaq
Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive - Law360
Pfizer CEO Tariff Uncertainty Hinders U.S. Investments - MSN
Pfizer CEO Albert Bourla Emphasizes National Security In US Drug Manufacturing - Benzinga
Pfizer (NYSE:PFE) Reports Q1 Earnings, Reaffirms 2025 Revenue Guidance at US$61-64 Billion - Yahoo Finance
Pfizer (PFE) Rating Upgraded: Signs of Stabilization Amid Strate - GuruFocus
Pfizer, BioNTech Fail to Void Alnylam’s Covid-Shot Patent Claims - Bloomberg Law News
Pfizer donates $750,000 to tribal health centers in Oklahoma - News On 6
Ibuprofen Drug Market Deep Research Report with Forecast by 2032 | Pfizer Inc., Johnson & Johnson, Bayer AG - openPR.com
Pfizer Inc. (NYSE:PFE) Q1 2025 Earnings Call Transcript - Insider Monkey
Is Pfizer Stock A Buy Or A Sell On Its Massive Savings Plan? - Investor's Business Daily
Fentanyl Drug Market Deep Research Report with Forecast by 2032 | - openPR.com
Pfizer Pulls Plug on Weight-Loss Pill Amid Health Concerns - CEO Today
Pfizer shifts to cost-cutting, new drug research after weight-loss bet fizzles - Crain's New York Business
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
Pfizer's Q1 Update May Mark A Bottom In The Stock (NYSE:PFE) - Seeking Alpha
Pfizer (PFE) Exceeds EPS Expectations, Faces Revenue Challenges - GuruFocus
Pfizer Inc (PFE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline and Strategic Growth - Yahoo Finance
Pfizer Reports Strong Q1 2025 Results and Reaffirms Guidance - TipRanks
Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away - Business Insider
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations? - Yahoo Finance
Pfizer’s Earnings Call: Growth Amidst Challenges - TipRanks
Pfizer CEO Bourla ‘Cautiously Optimistic’ About Tariffs, Pricing Policies - insights.citeline.com
Untruths? Tariffs? For Pfizer CEO, Nothing Trumps National Security 04/30/2025 - MediaPost
JPMorgan maintains Pfizer stock Neutral with $30 target By Investing.com - Investing.com India
PFIZER INC : JP Morgan is Neutral - marketscreener.com
Pfizer Cuts Spending on Weaker Sales - marketscreener.com
Viking Therapeutics (VKTX) Sees Boost After Pfizer's Acquisition Plans - GuruFocus
Health Care Stocks Rise As Pfizer And AstraZeneca Lead Gains - Finimize
Pfizer could make ‘tremendous investments’ in the US, but here’s why it’s choosing not to - TradingView
Pfizer Earnings Beat Isn’t Enough to Ease Stock Worries - Barron's
Viking among notable gainers as Pfizer raises deal prospects - MSN
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D - MSN
Pfizer Earnings: Expected Sales Decline Met With Solid Bottom-Line Growth From Cost Savings - Morningstar
Viking stock rises as Pfizer ups deal prospects (VKTX:NASDAQ) - Seeking Alpha
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):